Evidence Table G2. CONTINUOUS outcomes for class RETINOID (TOPICAL))/ANTI-BACTERIAL (TOPICAL).

Trial # Method		Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
		G.02.01			**Tretinoin + clindamycin**		**Clindamycin**		
46 Parallel	N=40 Mod/sev		**Severity (cook)**	Short (4)	Measure: 4		Measure: 3		
45	N=209		**Severity (cook)**	Short (4)	Measure: 4		Measure: 3		**NS**
47	N=162		**Severity (cook)**	Short (4)	Measure: 4		Measure: 4		
283 Parallel	N=64 Mild/mod/sev		**Dryness (severity)**	Short (6)	Measure: 1		Measure: 0		
			Erythema (severity)	Short (6)	Measure: 1		Measure: 0		**NS**
			Comedones change (%) Count location: Unspecified. Between P-value: T + C vs C: significant.	Mid (8)	Percent change: -48		Percent change: -20		**"Significant"**
			Dryness (severity)	Mid (8)	Measure: 2		Measure: 0		**NS**
			Erythema (severity)	Mid (8)	Measure: 1		Measure: 0		**NS**
			Papules change (%) Count location: Unspecified.	Mid (8)	Percent change: -52		Percent change: -53		**NS**
			Pustules change (%)	Mid (8)	Percent change: -60		Percent change: -62		**NS**
			Severity (cook)	Mid (8)	Measure: 4		Measure: 3		**NS**
47 Parallel	N=162 Mod/sev		**Inflammatory change (%)**	Mid (12)	Percent change: -64		Percent change: -57		**NS**
46	N=40		**Inflammatory change (%)**	Mid (12)	Percent change: -89		Percent change: -71		**NS**
45	N=209		**Inflammatory change (%)**	Mid (12)	Percent change: -76		Percent change: -58		**NS**
47	N=162		**Non-inflammatory change (%)**	Mid (12)	Percent change: -64		Percent change: -51		**0.04**
46	N=40		**Non-inflammatory change (%)**	Mid (12)	Percent change: -69		Percent change: -43		**NS**
45	N=209		**Non-inflammatory change (%)**	Mid (12)	Percent change: -69		Percent change: -61		**0.05**
			Severity (cook)	Mid (12)	Measure: 2		Measure: 2		**0.007**
47	N=162		**Severity (cook)**	Mid (12)	Measure: 2		Measure: 2		**0.001**
46	N=40		**Severity (cook)**	Mid (12)	Measure: 2		Measure: 2		**NS**
		G.02.02			**Tretinoin + Clindamycin**		**Tretinoin**		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
42 Parallel	N=40 Mod/sev	**Severity (cook)**	Short (4)	Measure: 3		Measure: 3		**NS**
43	N=161	**Severity (cook)**	Short (4)	Measure: 4		Measure: 4		**NS**
44	N=157	**Severity (cook)**	Short (4)	Measure: 4		Measure: 4		**NS**
43	N=161	**Inflammatory change (%)** Count location: Unspecified.	Mid (12)	Percent change: -72		Percent change: -55		**0.001**
42	N=40	**Inflammatory change (%)**	Mid (12)	Percent change: -81		Percent change: -53		**0.04**
44	N=157	**Inflammatory change (%)**	Mid (12)	Percent change: -62		Percent change: -48		**NS**
42	N=40	**Non-inflammatory change (%)**	Mid (12)	Percent change: -75		Percent change: -64		**NS**
44	N=157	**Non-inflammatory change (%)**	Mid (12)	Percent change: -68		Percent change: -65		**NS**
43	N=161	**Non-inflammatory change (%)**	Mid (12)	Percent change: -59		Percent change: -53		**NS**
42	N=40	**Severity (cook)**	Mid (12)	Measure: 1		Measure: 2		
43	N=161	**Severity (cook)**	Mid (12)	Measure: 2		Measure: 3		**0.009**
44	N=157	**Severity (Cook)**	Mid (12)	Measure: 2		Measure: 2		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.